Cargando…
Group I Paks as therapeutic targets in NF2-deficient meningioma
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors in the central nervous system, most notably schwannomas and meningiomas. Mutational inactivation of NF2 is found in 40–60% of sporadic meningiomas, but the molecular mechanisms underl...
Autores principales: | Chow, Hoi-Yee, Dong, Biao, Duron, Sergio G., Campbell, David A., Ong, Christy C., Hoeflich, Klaus P., Chang, Long-Sheng, Welling, D. Bradley, Yang, Zeng-jie, Chernoff, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385830/ https://www.ncbi.nlm.nih.gov/pubmed/25596744 |
Ejemplares similares
-
p21-activated kinase 1: PAK'ed with potential
por: Ong, Christy C., et al.
Publicado: (2011) -
Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer
por: Chow, H. Y., et al.
Publicado: (2018) -
Mouse models of PAK function
por: Kelly, Mollie L., et al.
Publicado: (2012) -
Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors
por: Araiza-Olivera, Daniela, et al.
Publicado: (2017) -
Temporal and Spatial Distribution of Activated Pak1 in Fibroblasts
por: Sells, Mary Ann, et al.
Publicado: (2000)